IQVIA Holdings Inc. Stock
€135.75
Your prediction
IQVIA Holdings Inc. Stock
Pros and Cons of IQVIA Holdings Inc. in the next few years
Pros
Cons
Performance of IQVIA Holdings Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
IQVIA Holdings Inc. | -1.280% | 1.851% | -15.060% | -38.672% | -28.790% | -34.800% | 2.901% |
Exact Sciences | 9.680% | 0.637% | 0.099% | -27.505% | -25.892% | -22.812% | -44.067% |
Regeneron Pharmaceuticals Inc. | 2.010% | 0.456% | -7.523% | -36.679% | -21.851% | -15.424% | 10.320% |
Incyte Corp. | -2.030% | 6.718% | -2.055% | 13.255% | -15.886% | -22.218% | -37.957% |

sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of IQVIA, a prominent entity in the Biotechnology and Medical Research industry, reflect a complex blend of strengths and challenges. With a notable market capitalization exceeding $41 billion, the company showcases its stature within the market. Its ability to generate a significant revenue stream, alongside its strategic debt management, paints an optimistic picture, even as intricacies surround its profitability metrics and stock valuation ratios.
Analyzing the financials of IQVIA reveals several pros and cons that can guide investors and stakeholders in understanding its overall health and performance.
*Pros: *
Comments
News

Iqvia Stock: Q4 Growth Signals Strong 2025 Outlook
Iqvia demonstrated robust performance in the fourth quarter of 2024, with revenue climbing 2.3% year-over-year to reach $3.96 billion. The company's Technology & Analytics Solutions segment emerged